Haemonetics Corp
HAE
View Detailed Chart
79.630USD
-0.380-0.47%
Market hours （ET）Quotes delayed by 15 min
3.72BMarket Cap
23.19P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.47%
5 Days
-0.34%
1 Month
-1.24%
6 Months
+8.49%
Year to Date
+1.99%
1 Year
+2.87%
View Detailed Chart
TradingKey Stock Score of Haemonetics Corp
Currency: USD Updated: 2025-12-24Key Insights
Haemonetics Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 26/206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 85.91.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Haemonetics Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
11
analysts
Buy
Current Rating
85.909
Target Price
+3.24%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Haemonetics Corp Highlights
StrengthsRisks
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 16.44% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.36B.
Undervalued
The company’s latest PE is 23.30, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 54.60M shares, decreasing 8.66% quarter-over-quarter.
Held by Joel Greenblatt
Star Investor Joel Greenblatt holds 22.93K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.27.
Haemonetics Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Haemonetics Corp Info
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
Ticker SymbolHAE
CompanyHaemonetics Corp
CEOSimon (Christopher A)
Websitehttps://www.haemonetics.com
FAQs
What is the current price of Haemonetics Corp (HAE)?
The current price of Haemonetics Corp (HAE) is 79.630.
What is the symbol of Haemonetics Corp?
The ticker symbol of Haemonetics Corp is HAE.
What is the 52-week high of Haemonetics Corp?
The 52-week high of Haemonetics Corp is 87.320.
What is the 52-week low of Haemonetics Corp?
The 52-week low of Haemonetics Corp is 47.315.
What is the market capitalization of Haemonetics Corp?
The market capitalization of Haemonetics Corp is 3.72B.
What is the net income of Haemonetics Corp?
The net income of Haemonetics Corp is 167.68M.
Is Haemonetics Corp (HAE) currently rated as Buy, Hold, or Sell?
According to analysts, Haemonetics Corp (HAE) has an overall rating of Buy, with a price target of 85.909.
What is the Earnings Per Share (EPS TTM) of Haemonetics Corp (HAE)?
The Earnings Per Share (EPS TTM) of Haemonetics Corp (HAE) is 3.433.
Related Instruments
+0.84%
-0.18%
-0.15%
-0.10%
-0.76%
-0.03%
-0.37%
-1.14%
+0.38%
+0.39%
+1.28%
+0.22%
+0.06%
-0.52%
-0.23%
+0.19%
-0.11%
-0.19%
-0.05%
+0.59%Popular Symbols
